On the 21st of March, 2012, Dr Alex Matter will be at Marina Bay Sands, Singapore, where he will be presenting at Drug Discovery World Asia 2012, part of a series of conferences at 5th Annual BioPharma Asia Convention 2012.
Professor Alex Matter, M.D., is CEO of the Experimental Therapeutics Centre, A*STAR, Singapore, having spent five and a half years as Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009. Prior to this role, Dr. Matter was Global Head of Oncology Research for Novartis Pharmaceuticals Corporation, Head of Novartis Institutes for BioMedical Research in Basel and Global Head of Translational Research. Dr. Matter played an important role in the success of several anticancer drugs, including Gleevec/GlivecÂ® and more recently, TasignaÂ®, building and leading the teams that discovered these and several other anticancer drugs as well as one HIV protease inhibitor (ReyatazÂ®) that is marketed by another company.
Dr Matter received his medical degree from the University of Basel. He also had fellowships at the Swiss National Science Foundation and the Swiss Academy for Medical Sciences. He has published more than 100 scientific articles and several book chapters in the area of oncology and hematology. He is emeritus Professor of the Medical Faculty of the University Basel and an Honorary Adjunct Professor of the Department of Pharmacology, YLL School of Medicine, NUS in Singapore. He is a member of the American Association for Cancer Research, the National Medical Research Council in Singapore, and the Board of Curiox, a Singapore-based start up company. He is also a member of several Scientific Advisory Boards. He is an elected member of the Swiss Academy of Medical Sciences. Dr. Matter is the recipient of the Life-time Achievement Award from IBC Life Sciences, the 13th Warren-Alpert prize and the AACR-Bruce F. Cain Memorial Award.
At the conference, Dr Matter will be speaking about the following:
Insights into next generation drug discovery in Singapore
1. Innovative discovery of drug targets focusing on oncology
2. Effective utilization of bundles of technology to discover hard targets